Carperitide Acetate 98%
89213-87-6
Chemical grade
98%
QINGDAO
1kg/20kg Red Iron Drum
2017-11-08
apis
-
Product Description
-
Seller Information
-
Description
Fields of Application
heart failure
Active Substance：
Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system
ECHEMI Editorial ReferenceAtrial Natriuretic Peptide (ANP) (1-28), human, porcine is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. ANP (1-28) inhibits endothelin-1 secretion in a dose-dependent way.
Carperitide is the α-human atrial natriuretic peptide (α-hANP) produced by recombinant technology. It was introduced in Japan as a treatment for acute congestive heart failure (CHF). In dogs with CHF, carperitide significantly reduced the elevated left ventricular end-diastolic pressure and the index of myocardial oxygen consumption (systolic blood pressure x heart rate). In a clinical trial, carperitide was effective in improving hemodynamics and symptoms in 60% of patients with acute CHF. Carperitide was reported to be well tolerated with no significant adverse effects clinically. A beneficial effect on hemodynamics has been reported in chronic heart failure patients. Carperitide is also in clinical trials for maintenance of blood pressure during surgical operations.
Atrial natriuretic peptide (ANP) is an endogenous peptide generated by proteolysis of prepro-ANP that is secreted by cardiomyocytes in the heart. It has effects on the renal and cardiovascular systems that decrease vasoconstriction, inhibit renin secretion, and increase sodium excretion. Human ANP binds to ANP receptors on cultured vascular smooth muscle cells (VSMCs) with a Kdvalue of approximately 1-2 nM and increases cGMP levels in a dose-dependent manner. It relaxes potassium-induced contraction of isolated canine renal arterial strips when used at concentrations of 10 and 100 ng/ml and dilates renal arteries in anesthetized dogs when used at doses ranging from 10 to 100 ng/kg. In a rat model of heart failure following experimental autoimmune myocarditis, human ANP,viaosmotic mini pump for 28 days, decreases cardiomyocyte size as well as the amount of cardiac fibrosis and left ventricular remodeling. ANP (1-28) (human) is a 28 amino acid peptide corresponding to the human protein sequence.
ChEBI: Carperitide is a polypeptide.Basic Info-
Product Name:
Carperitide
Other Name:ATRIAL NATRIURETIC PEPTIDE HUMAN;SER-LEU-ARG-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-MET: O-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR[SLRRSSCFGGR-MET: O-DRIGAQSGLGCNSFRY]DISULFIDE BRIDGE CYS7-CYS23.;Carperitide Acetate, carperitida;Atrial Natriuretic Peptide (1-28) (human) (trifluoroacetate salt);ahANF, Carperitide;H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH;Atrial natriureticpeptide-28 (huMan) (9CI);Atrial Natriuretic Factor (1-28) (huMan) αhANF, Carperitide
CAS No.:89213-87-6
Molecular Formula:C127H203N45O39S3
InChIKeys:NSQLIUXCMFBZME-VUEHYBQXNA-N
Molecular Weight:3080.44
Exact Mass:3078.444580
EC Number:686-482-9
Categories:
Characteristics-
PSA:
1479.28000
XLogP3:-14.30
Density:1.55±0.1 g/cm3(Predicted)
Refractive Index:1.689
Critical Temperature & Pressure:Store at -20°C
Hazard IdentificationClassification of the substance or mixture
Reproductive toxicity, Category 2
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H361 Suspected of damaging fertility or the unborn child
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
apis
-
Payment Terms:
D/P,L/C
-
Average lead Time:
60
-
Total Annual Revenue:
Less than $1 million
Shenzhen JYMed Technology Co., Ltd. (JYMed) founded in 2009, is an innovative pharmaceutical enterprise with independent intellectual property rights in R&D, manufacturing and commercialization of peptide products. There are two subsidiary companies of Shenzhen JX Bio Pharmaceutical Co., Ltd. and Hubei JX Bio Pharmaceutical Co., Ltd. It is initiative to establish the R&D technology platform for peptide products and sustained release pharmaceutical preparation of peptide and protein medicines by JYMed in China. The peptide products in R&D are in the forward position in China and aboard, while the technology is in the domestic leading position and international advanced level.
The company has an excellent R&D team, management team and first-class expert consultant team consisting of doctors, masters, professors, researchers, senior engineers and other professionals. Meanwhile, to maximally extend the R&D team by hiring top industry scientists to serve as visiting researchers, commissioners, and technical consultants and strengthening technical cooperation with scientific research units. It has established a good cooperative relationship with the University of Pittsburgh, the United States, Michigan State University, the University of Maryland, Peking University, Tsinghua University and other well-known domestic and foreign institutions and scientific research institutions.
The company has passed the certification of Shenzhen High-tech Enterprise and National High-tech Enterprise. As a domestic enterprise with the advantage of the industrialization of polypeptide APIs, it has achieved a major technological breakthrough in the industrialization of polypeptide APIs with extremely high technical difficulty. With high-quality product quality, the company carries out open R&D CRO services. The market network covers domestic and foreign markets. The cooperation customers are mainly domestic and foreign large-scale new drug R&D and production companies.
In recent years, JYMedhas been focusing on R&D and production of peptide. At the same time, the company also has been focusing on the development and industrialization. It has been continually increasing investment in high-end chemical drugs and biological drugs, striving for long-term business operations and develop in an all-round way to create a more prominent corporate competitive advantage.
The company is adhering to the enterprise spirit of “Tianjianzhishan, Tianyuanzhihe.” We are with a grateful heart and commit to providing reliable medical products for human health all the time. To work hard to become an influential and innovative company in the pharmaceutical industry.
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product